In the 1990s, Stanford's Irv Weissman created a unique way to grow and deliver blood stem cells to desperate patients with aggressive cancers, boosting survival rates. But then the discovery itself died -- a victim of the heartbreaking economics of commercial stem-cell development, where the long and rocky road of research, especially in the field of "personalized medicine," often discourages investment.